These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

334 related items for PubMed ID: 29328472

  • 1. Combined analysis of gene expression and genome binding profiles identified potential therapeutic targets of ciclopirox in Ewing sarcoma.
    Yuan B, Ji W, Xia H, Li J.
    Mol Med Rep; 2018 Mar; 17(3):4291-4298. PubMed ID: 29328472
    [Abstract] [Full Text] [Related]

  • 2. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
    Hensel T, Giorgi C, Schmidt O, Calzada-Wack J, Neff F, Buch T, Niggli FK, Schäfer BW, Burdach S, Richter GH.
    Oncotarget; 2016 Jan 12; 7(2):1451-63. PubMed ID: 26623725
    [Abstract] [Full Text] [Related]

  • 3. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN, Tang N, Fleming JT, Ma Y, Guo Y, Borinstein SC, Chiang C, Wang J.
    Oncotarget; 2016 Jul 12; 7(28):43504-43517. PubMed ID: 27259270
    [Abstract] [Full Text] [Related]

  • 4. PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.
    Giorgi C, Boro A, Rechfeld F, Lopez-Garcia LA, Gierisch ME, Schäfer BW, Niggli FK.
    Oncotarget; 2015 Oct 06; 6(30):28895-910. PubMed ID: 26336820
    [Abstract] [Full Text] [Related]

  • 5. Systems biology of Ewing sarcoma: a network model of EWS-FLI1 effect on proliferation and apoptosis.
    Stoll G, Surdez D, Tirode F, Laud K, Barillot E, Zinovyev A, Delattre O.
    Nucleic Acids Res; 2013 Oct 06; 41(19):8853-71. PubMed ID: 23935076
    [Abstract] [Full Text] [Related]

  • 6. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability.
    He T, Surdez D, Rantala JK, Haapa-Paananen S, Ban J, Kauer M, Tomazou E, Fey V, Alonso J, Kovar H, Delattre O, Iljin K.
    Gene; 2017 Jan 05; 596():137-146. PubMed ID: 27760381
    [Abstract] [Full Text] [Related]

  • 7. Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma.
    Niedan S, Kauer M, Aryee DN, Kofler R, Schwentner R, Meier A, Pötschger U, Kontny U, Kovar H.
    Oncogene; 2014 Jul 24; 33(30):3927-38. PubMed ID: 23995784
    [Abstract] [Full Text] [Related]

  • 8. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.
    Grohar PJ, Segars LE, Yeung C, Pommier Y, D'Incalci M, Mendoza A, Helman LJ.
    Clin Cancer Res; 2014 Mar 01; 20(5):1190-203. PubMed ID: 24277455
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of the oncogenic fusion protein EWS-FLI1 causes G2-M cell cycle arrest and enhanced vincristine sensitivity in Ewing's sarcoma.
    Zöllner SK, Selvanathan SP, Graham GT, Commins RMT, Hong SH, Moseley E, Parks S, Haladyna JN, Erkizan HV, Dirksen U, Hogarty MD, Üren A, Toretsky JA.
    Sci Signal; 2017 Oct 03; 10(499):. PubMed ID: 28974650
    [Abstract] [Full Text] [Related]

  • 10. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.
    Kovar H.
    Expert Opin Ther Targets; 2014 Nov 03; 18(11):1315-28. PubMed ID: 25162919
    [Abstract] [Full Text] [Related]

  • 11. Development of an Ewing sarcoma cell line with resistance to EWS‑FLI1 inhibitor YK‑4‑279.
    Conn E, Hour S, Allegakoen D, Graham G, Petro J, Kouassi-Brou M, Hong SH, Selvanathan S, Çelik H, Toretsky J, Üren A.
    Mol Med Rep; 2020 Mar 03; 21(3):1667-1675. PubMed ID: 32016454
    [Abstract] [Full Text] [Related]

  • 12. Functional Genomic Screening Reveals Splicing of the EWS-FLI1 Fusion Transcript as a Vulnerability in Ewing Sarcoma.
    Grohar PJ, Kim S, Rangel Rivera GO, Sen N, Haddock S, Harlow ML, Maloney NK, Zhu J, O'Neill M, Jones TL, Huppi K, Grandin M, Gehlhaus K, Klumpp-Thomas CA, Buehler E, Helman LJ, Martin SE, Caplen NJ.
    Cell Rep; 2016 Jan 26; 14(3):598-610. PubMed ID: 26776507
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetic modeling optimizes inhibition of the 'undruggable' EWS-FLI1 transcription factor in Ewing Sarcoma.
    Hong SH, Youbi SE, Hong SP, Kallakury B, Monroe P, Erkizan HV, Barber-Rotenberg JS, Houghton P, Üren A, Toretsky JA.
    Oncotarget; 2014 Jan 30; 5(2):338-50. PubMed ID: 24481407
    [Abstract] [Full Text] [Related]

  • 14. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.
    Theisen ER, Pishas KI, Saund RS, Lessnick SL.
    Oncotarget; 2016 Apr 05; 7(14):17616-30. PubMed ID: 26848860
    [Abstract] [Full Text] [Related]

  • 15. Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma.
    Goss KL, Gordon DJ.
    Oncotarget; 2016 Sep 27; 7(39):63003-63019. PubMed ID: 27557498
    [Abstract] [Full Text] [Related]

  • 16. RETRACTED: Combining PARP-1 inhibition and radiation in Ewing sarcoma results in lethal DNA damage.
    Lee HJ, Yoon C, Schmidt B, Park DJ, Zhang AY, Erkizan HV, Toretsky JA, Kirsch DG, Yoon SS.
    Mol Cancer Ther; 2013 Nov 27; 12(11):2591-600. PubMed ID: 23966622
    [Abstract] [Full Text] [Related]

  • 17. Pharmaceutical Interference of the EWS-FLI1-driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma.
    Heisey DAR, Jacob S, Lochmann TL, Kurupi R, Ghotra MS, Calbert ML, Shende M, Maves YK, Koblinski JE, Dozmorov MG, Boikos SA, Benes CH, Faber AC.
    Mol Cancer Ther; 2021 Oct 27; 20(10):1868-1879. PubMed ID: 34315769
    [Abstract] [Full Text] [Related]

  • 18. MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor.
    Franzetti GA, Laud-Duval K, Bellanger D, Stern MH, Sastre-Garau X, Delattre O.
    Oncogene; 2013 Aug 15; 32(33):3915-21. PubMed ID: 22986530
    [Abstract] [Full Text] [Related]

  • 19. EWS-FLI1 and Menin Converge to Regulate ATF4 Activity in Ewing Sarcoma.
    Jiménez JA, Apfelbaum AA, Hawkins AG, Svoboda LK, Kumar A, Ruiz RO, Garcia AX, Haarer E, Nwosu ZC, Bradin J, Purohit T, Chen D, Cierpicki T, Grembecka J, Lyssiotis CA, Lawlor ER.
    Mol Cancer Res; 2021 Jul 15; 19(7):1182-1195. PubMed ID: 33741715
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.